ArticleACS medicinal chemistry letters2017
Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.
Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Applications of Bridgehead Heterocycles in Drug Design and Medicinal Chemistry.Topics in current chemistry (Cham) · 2025Review
- Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.Cellular and molecular life sciences : CMLS · 2025Review
- Limited high-throughput screening compatibility of the phenuivirus cap-binding domain.Scientific reports · 2023Article
- Synthesis of Blue Emissive Quaternary 9,9-DisubstitutedACS omega · 2023Article
- Cyclobutanes in Small-Molecule Drug Candidates.ChemMedChem · 2022Review
- Azaindole therapeutic agents.Bioorganic & medicinal chemistry · 2020Article
- Investigation of Binding Affinity between Potential Antiviral Agents and PB2 Protein of Influenza A: Non-equilibrium Molecular Dynamics Simulation Approach.International journal of medical sciences · 2020Article
- Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection.Bioorganic & medicinal chemistry letters · 2019Article
- Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development.Current medicinal chemistry · 2019Review
- Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors.Nucleic acids research · 2018Article
- Mechanochemical enzymatic resolution ofBeilstein journal of organic chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In our efforts to develop novel small-molecule inhibitors for the treatment of influenza, we utilized molecular modeling and the X-ray crystal structure of the PB2 subunit of the influenza polymerase to optimize a series of acyclic β-amino acid inhibitors, highlighted by compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.